Sepracor, Barr Clash Over Asthma Drug
Sepracor Inc. has asserted five patents against generic drug maker Barr Laboratories Inc. in a bid to stave off competition in the $600 million annual market for the inhaled asthma treatment...To view the full article, register now.
Already a subscriber? Click here to view full article